IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company, today announced that the U.S. Food and Drug ...
The US Food and Drug Administration (FDA) recently issued three warning letters to facilities in China, the US, and India for ...
AUVELITY is a first-in-class treatment, which targets the NMDA and sigma-1 receptors, approved for agitation associated with dementia due to ...
DOJ moves medical cannabis to Schedule III; biotech firms eye funding and IPOs amid banking and tax uncertainty.
A federal push to ban gender-affirming care has Illinois lawmakers considering changes to a state drug monitoring program.
In a landmark week for medical innovation, the FDA approved or cleared multiple breakthrough technologies, from the first gene therapy for genetic hearing loss to a wireless brain implant trial for ...
Establishes a vertically integrated platform spanning pharmaceutical-grade botanical drug development and global consumer ...
The patient death occurred outside the U.S. and was deemed unrelated to Newron Pharmaceuticals’ investigational schizophrenia ...
Amgen on Thursday reported first-quarter product sales rose 4%, helped by demand for cholesterol and rare disease medicines, ...
10h
FDA approval, fundraising, and the reality of building in healthcare according to BioticsAI founder
BioticsAI CEO Robhy Bustami joined Isabelle Johannessen on Build Mode to discuss how the company has navigated a highly ...
Federal judge permanently blocks North Dakota 340B drug law, ruling it unconstitutional and halting enforcement against drugmakers and PhRMA members.
Omitting employers from a drug pricing working group would be a mistake, healthcare professionals Shawn Gremminger and David ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results